Last reviewed · How we verify

NCT03684759: EXPIRE

Sputum Validation for the Molecular Diagnosis of Respiratory Viral Infections in Cystic Fibrosis

Completed Last updated 26 September 2018
What this trial tests

trial in Cystic Fibrosis in 30 participants. Completed in 6 February 2017.

Timeline
24 February 2016
Primary endpoint
6 February 2017
6 February 2017

Quick facts

Lead sponsorUniversity Hospital, Brest
StatusCompleted
Study typeOBSERVATIONAL
Enrollment30
Start date24 February 2016
Primary completion6 February 2017
Estimated completion6 February 2017
Sites3 locations across France

Conditions studied

Sponsor

University Hospital, Brest

Who can join

Eligibility, any sex, with Cystic Fibrosis or Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this pilot study is to demonstrate the feasibility of viral biomolecular diagnosis in sputum compared to nasopharyngeal swab in cystic fibrosis acute respiratory infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

Other University Hospital, Brest trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03684759.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing